title: Concurrent chemoradiotherapy with docetaxel for T2 laryngeal carcinoma.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of concurrent chemoradiotherapy with docetaxel (DOC) for T2 laryngeal carcinoma.
  
  
  METHODS
  Twelve patients with T2 laryngeal cancer received concurrent chemoradiotherapy (60-70Gy) with weekly DOC (10 mg/m2) (CCRT group). The clinical files of the patients were retrospectively reviewed and survival rates and laryngeal preservation rates were analyzed compared with the group treated with conventional radiation therapy alone (RT group).
  
  
  RESULTS
  Complete response was observed in 11 of 12 patients (91.7%) in the CCRT group. Overall 5-year survival rates by Kaplan-Meier's method were 90% for the CCRT group and 78% for the RT group. The disease free survival with anterior commisure involvement was 90% in CCRT group and 53% in RT group, respectively. Toxicity over grade III was noticed in 3 patients.
  
  
  CONCLUSIONS
  Concurrent chemoradiotherapy with DOC is a feasible and effective treatment modality for organ preservation in T2 laryngeal cancer in the outpatient setting. Efficacy and safety of this treatment modality in an outpatient setting were discussed.
authors.affiliation: Department of Otolaryngology, School of Medicine, Tokai University, Isehara, Japan. okami@is.icc.u-tokai.ac.jp
authors.forename: Kenji
authors.initials: K
authors.lastname: Okami
authors.forename: Takahide
authors.initials: T
authors.lastname: Hamano
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Takeo
authors.forename: Akihiro
authors.initials: A
authors.lastname: Sakai
authors.forename: Junichi
authors.initials: J
authors.lastname: Onuki
authors.forename: Kyoko
authors.initials: K
authors.lastname: Odagiri
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Tamai
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ohizumi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iida
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000532:radiotherapy*; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel